Year in Review | Published:

Cancer immunotherapy in 2017

The breakthrough of the microbiota

Nature Reviews Immunology volume 18, pages 8788 (2018) | Download Citation

In 2017, epidemiological studies in humans and experiments in mouse models showed that the intestinal microbiota determines the effectiveness of anticancer immunotherapies. As such the microbiota offers new prognostic biomarkers and shows promise as a target for future antineoplastic treatments.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. Mining the human gut microbiota for immunomodulatory organisms. Cell 168, 928–943 (2017).

  2. 2.

    et al. A single-cell survey of the small intestinal epithelium. Nature 551, 333–339 (2017).

  3. 3.

    et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017).

  4. 4.

    et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563 (2017).

  5. 5.

    et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).

  6. 6.

    et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J. Clin. Oncol. 35, 1650–1659 (2017).

  7. 7.

    et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

  8. 8.

    et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).

  9. 9.

    et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).

  10. 10.

    et al. Anticancer effects of the microbiome and its products. Nat. Rev. Microbiol. 15, 465–478 (2017).

  11. 11.

    et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).

Download references


The authors are supported by grants from the Institut National contre le Cancer, Ligue Nationale contre le Cancer, Swiss Bridge Foundation, ISREC, RHU-TORINO-LUMIERE, SIRIC Socrates at Gustave Roussy and Seerave Foundation.

Author information


  1. Guido Kroemer is at Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers; Paris, France; Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus; Villejuif, France; INSERM U1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité; Paris, France; Université Pierre et Marie Curie, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; and Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.

    • Guido Kroemer
  2. Laurence Zitvogel is at INSERM U1015, labellisée Ligue Française Contre le Cancer, Université Paris-Saclay, Gustave Roussy Immuno-Oncology Programme, Paris, France.

    • Laurence Zitvogel


  1. Search for Guido Kroemer in:

  2. Search for Laurence Zitvogel in:

Competing interests

G.K and L.Z. are co-founders of everImmune, a biotech company that identifies bacteria for cancer treatment.

Corresponding authors

Correspondence to Guido Kroemer or Laurence Zitvogel.

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing